TACIT THERAPEUTICS, INC.
Biotech · Private
RNA editing therapeutic for Dravet syndrome that corrects defective SCN1A sequences in inhibitory neurons
- Grants
- $999K
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 20
- 1 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Repurposing RNA processing factors to edit RNA for the treatment of Dravet syndrome | $999,255 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2260 | Origin Speech Therapy Inc. | — | $2.6M |
| 2261 | TRAMPOLINE PHARMA, INC. | — | — |
| 2262 | HEMATHERIX LLC | — | — |
| 2263 | TACIT THERAPEUTICS, INC. | — | — |
| 2264 | SOTERIA SYSTEMS, INC. | — | $2.7M |
| 2265 | LineaGen, Inc | — | $38M |
| 2266 | GPER G-1 Development Group LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Systems And Methods For Promoting Trans-splicingapplication
- Localization Of Trans-splicing Nucleic Acid Molecules To And Within The Cellular Nucleusapplication
- Stabilization Of Therapeutic Trans-splicing Rna Molecules In Human Cellsapplication
- Rna Editing Via Recruitment Of Spliceosome Componentsapplication
- Rna Editing Via Recruitment Of Spliceosome Componentsgranted
- High Efficiency Trans-splicing For Replacement Of Targeted Rna Sequences In Human Cellsapplication
- Trans-splicing System For Tissue-specific Replacement Of Rna Sequencesapplication
- Rna Editing Via Recruitment Of Spliceosome Componentsapplication
- Systems And Methods For Promoting Trans-splicingapplication
- Rna Editing Via Localization Of Trans-splicing Rna Molecules To And Within The Cellular Nucleusapplication
- Stabilization Of Therapeutic Trans-splicing Rna Molecules In Human Cellsapplication
- Rna Editing Via Recruitment Of Spliceosome Componentsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.